From: Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study
Drug | Duration of medication | Overaall number of cases | AST (U/L) | ALT (U/L/) | ALP (U/L) | GGT (U/L) | Cases with ALT > 3 | Cases with ALT > 5 |
---|---|---|---|---|---|---|---|---|
Methotrexate | 10 weeks (4–20) | 9 | 77 (30–128) | 170 (62–382) | 100 (43–234) | 63 (23–152) | 1 |  |
Azathioprine | 5.5 weeks (3–9) | 9 | 383 (69–1165) | 280 (113–594) | 260 (43–613) | 768 (38–2143) |  | 3 |
Mesalamine | 15 weeks (13–17) | 3 | 63 (51–75) | 97 (71–123) | 83 (78–88) | 45 (42–48) |  |  |